TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...
centerforbiosimilars14h
FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...